Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis
This study will explore the efficacies of several practical short-term (peri-procedural) intravenous fluid regimens in the prevention of post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). PEP is the most common serious ERCP-related adverse event (AE), occurring in 5-15% of patients, and associated with significant morbidity, mortality, and healthcare utilization. Given the current lack of data on effectiveness of short-term fluid regimens in PEP prevention to inform practice, the results of the proposed study have the strong potential to impact ERCP practices worldwide, whether positive or negative.
- EligibilityCriteria: Inclusion Criteria:  age 18-75 years (due to higher likelihood of undiagnosed cardiac disease or renal insufficiency in patients >75 years of age) ability to give informed consent native major papillary anatomy ability and willingness to obtain bloodwork the day after ERCP  Exclusion Criteria:  prior ERCP with sphincterotomy and/or sphincteroplasty confirmed or suspected cholangitis or sepsis confirmed pancreatitis, hyperlipasemia, or hyperamylasemia within the preceding 7 days NYHA Class II or greater heart failure active pulmonary edema myocardial infarction or ischemia within the preceding 3 months renal insufficiency with CrCl < 40 mL/minute CPT Class B or C cirrhosis and/or end-stage liver disease room air oxygen saturation <90% or requirement of home O2 hypernatremia with Na+ ≥ 150 mEq/L or Na+ <130 mEq/L uncontrolled hypertension or hypotension pregnant status - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult